October 2021: Cabozantinib (Cabometyx, Exelixis, Inc.) has been approved by the Food and Drug Administration for adult and paediatric patients 12 years of age and older who have locally advanced or me...
cabozantinib
On January 14, 2019, cabozantinib (CABOMETYX, Exelixis, Inc.) was approved by the Food and Drug Administration for patients with hepatocellular carcinoma (HCC) who have previously been treat...
cabozantinib
Medullary Thyroid Cancer Treatment
Medullary thyroid cancer (MTC) is an aggressive but rare type of thyroid cancer that develops from the parafollicular C cells of the thyroid gland. In contrast to o...
cabozantinib
According to a study published in the New England Journal of Medicine published on July 5, Cabozantinib's overall and progression-free survival in patients with advanced hepatocellular carcinoma was s...
cabozantinib